Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Prior treatment

• Patients that have any contraindication or are not eligible for treatment with brolucizumab as according to the SmPC
• Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
• Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
• Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline

Other illness

• Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
• Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 24 months study participation

Other

• Patients treated for RVO or CNV other than nAMD
• Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
• Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis \>50% of the total lesion (nAMD)
• Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
• Patients participating in parallel in an interventional clinical trial
• Pregnancy and breast-feeding

• The unit of analysis is patient-eye, i.e. all criteria should be applied to the study eye, unless otherwise specified. Patients will be included in the study if they fulfil the following requisites:
• Diagnosis of nAMD or visual impairment due to DME
• Male and Female nAMD and DME patients with ≥18 years of age at index
• Decision to treat with brolucizumab at baseline visit
• Signed written informed consent
• Patients for whom a therapy with brolucizumab is medically indicated
• Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening